Linda Burkly, Executive Vice President and Chief Scientific Officer of Editas Medicine, Inc. (NASDAQ:EDIT), filed a Form 4 on September 4, 2026, disclosing the sale of 709 shares of common stock on September 3, 2026, in connection with the vesting of restricted stock units.
Key Highlights
- Shares sold: 709 shares of Editas Medicine common stock were disposed of on September 3, 2026.
- Weighted average price: Shares were sold at a weighted average price of $3.0372, with individual trades ranging from $3.0050 to $3.0372.
- Tax withholding purpose: According to the filing, the sale represents shares sold by the issuer to meet tax withholding obligations resulting from the vesting of restricted stock units on September 2, 2026.
- Automatic sales plan: The sale was effected pursuant to a durable automatic sales instruction plan adopted by Burkly on July 3, 2023.
- Resulting ownership: Following the transaction, Burkly directly beneficially owns 61,660 shares of common stock.
- Non-discretionary: The filing states the sale "does not represent a discretionary trade by the Reporting Person."
Editas Medicine CSO Reports RSU Vesting and Tax-Withholding Sale
Linda Burkly, serving as Executive Vice President and Chief Scientific Officer of Editas Medicine, Inc., reported a single non-derivative securities transaction in her Form 4 filing. The transaction involved the sale of 709 shares of Editas Medicine common stock on September 3, 2026, at a weighted average price of $3.0372 per share. The filing notes the transaction was executed across multiple trades at prices ranging from $3.0050 to $3.0372.
According to the filing, the sale was carried out under a durable automatic sales instruction plan that Burkly adopted on July 3, 2023, and was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). The filing describes the sale as shares sold by the issuer to cover tax withholding obligations triggered by the vesting of restricted stock units on September 2, 2026. The filing explicitly states the sale "does not represent a discretionary trade by the Reporting Person."
Burkly undertook, per the filing, to provide upon request to the SEC staff, the issuer, or a security holder full information regarding the number of shares and the prices at which the transaction was effected. Following the reported transaction, Burkly's direct beneficial ownership of Editas Medicine common stock stands at 61,660 shares, according to the filing. No derivative securities transactions were reported in this filing.
What Was Disclosed
The filing discloses a sale of 709 shares of Editas Medicine common stock by the company's Chief Scientific Officer on September 3, 2026, at a weighted average price of $3.0372, conducted automatically to cover RSU vesting tax obligations, leaving her with 61,660 shares directly held.


Please wait processing your request...